Core Viewpoint - Aier Eye Hospital Group (300015.SZ) has approved the acquisition of partial equity in 39 institutions, including Bozhou Aier and Lianyungang Aier, with a total transaction amount of 963.0228 million yuan, funded by its own capital [1] Group 1: Strategic Goals - The company is focused on enhancing operational levels and deepening the "graded chain" development model to improve service coverage [1] - The company aims to achieve its mission of ensuring eye health rights for all, regardless of wealth, through both organic growth and external mergers and acquisitions [1] Group 2: Market Positioning - External mergers and acquisitions are crucial for increasing market share and competitiveness, helping to solidify the company's leading position in the ophthalmology market [1] - The acquisition is expected to accelerate the national network construction and improve the layout of service points, thereby strengthening the company's development foundation [1]

Group 1 - The core point of the article is that Aier Eye Hospital (SZ 300015) announced a board meeting to discuss the acquisition of partial equity in 39 institutions, including Bozhou Aier and Lianyungang Aier [1] - For the year 2024, Aier Eye Hospital's revenue composition is reported to be 99.65% from the medical industry and 0.35% from other businesses [1] - As of the report date, Aier Eye Hospital has a market capitalization of 103.7 billion yuan [2]

为抓住医疗行业发展的良好机遇，在未来竞争中占得先机，同时，基于标的 项目的基础条件和发展趋势，公司拟收购 39 家机构的部分股权，有利于尽快完 善区域市场布局，形成规模效应，进一步深化在全国各地的"分级连锁"体系， 巩固和提升公司的领先地位。 证券代码：300015 股票简称：爱尔眼科 公告编号：2025-101 爱尔眼科医院集团股份有限公司 第七届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）第七届董事会第二次会 议于 2025 年 12 月 24 日以通讯表决方式召开，会议通知于 2025 年 12 月 21 日以 邮件方式送达，会议由董事长陈邦先生召集。应到董事 7 人，实到董事 7 人，会 议的召开符合《公司法》和《公司章程》的有关规定，会议合法、有效。经审议， 本次会议一致通过如下议案： 《关于收购亳州爱尔、连云港爱尔等 39 家机构部分股权的议案》 本次交易以自有资金支付，交易合计金额为 96,302.28 万元。 本次交易不构成关联交易，不构成重大资产重组。本次交易未达到 ...

证券代码：300015 股票简称：爱尔眼科 公告编号：2025-102 爱尔眼科医院集团股份有限公司 关于收购亳州爱尔、连云港爱尔等 39 家机构部分股权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 12 月 24 日召开第七届董事会第二次会议，审议通过《关于收购亳州爱尔、连云港爱尔等 39 家机构部分股权的议案》，本次交易以自有资金支付，交易合计金额为 96,302.28 万元。 本次交易不构成关联交易，不构成重大资产重组。本次交易未达到股东会议 事范围，经公司董事会审议批准后即可实施。 一、交易概述 本次交易中的交易对方、标的公司、收购对价、收购比例、收购完成后上市 公司 持股比例情况如下： 1 | 序号 | 交易对方 | 标的医院 | 收购对价（万元） | 收购比例 | 收购后上市公司持股比例 | | --- | --- | --- | --- | --- | --- | | 1 | | 亳州爱尔眼科医院有限公司 | 3,257.92 | 80.0000% | 80.0000% ...

Group 1 - The core viewpoint emphasizes that listed companies in China are not only the main force behind data growth but also serve as a stabilizing factor in the industry ecosystem, focusing on long-term value and comprehensive governance [2] - In 2025, the capital market aims for steady progress and quality improvement amidst multiple risks, enhancing market resilience and risk resistance, leading to reasonable quantitative growth and effective qualitative enhancement [2] - The market's expectations for listed companies have shifted from short-term performance to long-termism and comprehensive value, including governance structure, stable returns, strategic layout in frontier fields, and deep ESG practices [2] Group 2 - The 2025 T-EDGE Global Dialogue, organized by Titanium Media Group, NextFin.AI, and Barron’s China, highlights the importance of recognizing companies that redefine industry boundaries and emphasizes the core logic of "value investment" [3] - The EDGE AWARDS annual list includes categories such as Most Socially Responsible Company, Best Board Secretary, Most Investment Value Company, and Best Investor Relations Management Company, recognizing outstanding performance in governance, investment value, social responsibility, and investor relations [3][4] Group 3 - Aier Eye Hospital is recognized as a leader in ESG practices, integrating ESG into its core business and governance structure, while actively engaging in public welfare projects to enhance national eye health [5] - Betaini Group focuses on creating a skin health ecosystem and incorporates green development into its strategy, promoting biodiversity and sustainable practices [6] - Kweichow Moutai leads the liquor industry with a brand value of 468.718 billion, actively engaging in ecological protection and social responsibility initiatives [7] - JD Group has created significant employment opportunities and is committed to improving living conditions for its delivery personnel, with plans to invest 22 billion in housing projects [8] - Quantitative Group, listed on the Hong Kong Stock Exchange, leverages AI technology to reshape online consumption and has achieved a compound annual growth rate of 44.59% in revenue from 2022 to 2024 [9] - Seres focuses on new energy vehicles and has established a robust ESG governance framework, with significant growth in revenue and sales projected for 2024 [10] - Shui Jing Fang integrates social responsibility into its corporate strategy, setting clear environmental goals and contributing to community development [11] - China Baoan actively engages in social responsibility through its subsidiaries, contributing to community welfare and healthcare improvements [13] Group 4 - The Best Board Secretary category highlights the importance of effective communication between listed companies and the public, emphasizing the role of board secretaries in enhancing corporate governance [14] - Ren Shunying from Anfu Technology is recognized for her expertise in capital operations and corporate governance, significantly contributing to the company's compliance and investor relations [15] - Xia Ping from Jiahe Intelligent is noted for her effective investor relations management and participation in strategic planning [16] - Li Liangyu from Robotech is acknowledged for his role in maintaining corporate governance and enhancing market recognition [17] - Zhang Wenyu from Tianqi Lithium is recognized for his contributions to market value management and investor relations [18] Group 5 - The Most Investment Value Company category identifies companies with clear business models and significant breakthroughs in technology or policy, indicating strong growth potential [19][20] - Orbbec, a leader in 3D vision technology, has achieved over 70% market share in key sectors and continues to lead industry advancements [20] - BYD maintains its position as a global leader in new energy, with significant growth in overseas markets and a strong investment outlook [21] - Cambrian has entered a critical profitability phase, with substantial revenue growth and a strong market position in AI chips [22] - Hanlan Environment focuses on environmental services and has achieved consistent profit growth, attracting long-term investors [23] - Geely Auto has demonstrated strong financial performance and strategic integration, positioning itself for sustained growth [24] - Kanghong Pharmaceutical emphasizes innovation in drug development and has shown robust revenue growth, indicating long-term investment value [25] - Lens Technology maintains a strong market position with solid cash flow and growth potential in the automotive and consumer electronics sectors [26]

图表一：爱尔眼科WINDESG评级 在刚刚公布的格隆汇"金格奖"名单上，爱尔眼科（300015.SZ）同时出现在两个重磅奖项的揭晓时刻：公司获评"年度 ESG先锋奖（大市值）"，董事会秘书吴士君荣获"年度卓越董秘"。 这并非偶然的叠加。在关注企业综合表现的价值评价体系中，这两项荣誉如同一体两面：一面关注企业如何与社会、 环境和谐共生（ESG），另一面看重企业如何与股东、市场保持良好沟通（治理）。当一家公司能在这两个层面均受 到高度认可，往往反映出其运营中蕴含的深层稳健基因与可持续的发展动力。 | 2025年度卓越公司评选榜单 | | | | | | --- | --- | --- | --- | --- | | UCLUB OUTSTANDING COMPA | | | | | | 公司名称 | 公司代码 | 公司名称 | 公司代码 | | | 爱尔眼科 | 300015:SZ | 同程旅行 | 00780.HK | | | 贝壳 | 02423.HK/BEKE.US | 潍柴动力 | 000338.SZ/02338.HK | | | 波司登 | 03998.HK | 中国飞鹤 | 06186.HK | | ...

| | 2025年度卓越公司评选榜单 | | | | --- | --- | --- | --- | | | 度 ESG先 | | | | | UB OUTSTANDING COMP | | | | 公司名称 | 公司代码 | 公司名称 | 公司代码 | | 爱尔眼科 | 300015:SZ | 同程旅行 | 00780.HK | | 贝壳 | 02423.HK/BEKE.US | 潍柴动力 | 000338.SZ/02338.HK | | 波司登 | 03998.HK | 中国飞鹤 | 06186.HK | | 蒙牛乳业 | 02319.HK | 中国建筑国际 | 03311.HK | | 宁德时代 | 300750.SZ/03750.HK | 中国重汽 | 03808.HK | | | 排名不分先后 | | | 在刚刚公布的格隆汇"金格奖"名单上，爱尔眼科（300015.SZ）同时出现在两个重磅奖项的揭晓时刻：公司获评"年度 ESG先锋奖（大市值）"，董事会秘书吴士君荣获"年度卓越董秘"。 这并非偶然的叠加。在关注企业综合表现的价值评价体系中，这两项荣誉如同一体两面：一面关注企业如何与社会、 环境和谐共生 ...

中国经济网北京12月23日讯 吉林省药品监督管理局网站近期发布吉林省医疗器械质量公告（2025年第2期）。为加强医疗器械质量监督管理，保障医 疗器械产品使用安全有效，吉林省药品监督管理局在全省范围内组织开展质量抽查检验，现将本期不合格产品信息予以公告。药品监督管理部门已要求相关 单位采取风险防控措施，对不合格产品依据相关法律法规进行查处。 其中，上海天意医疗器械有限公司生产的眼部热敷贴最高温度项目不合格，被抽样单位为大安爱尔眼科医院有限公司，规格/型号为185mm×75mm，生 产日期为2024年12月30日，批号/出厂编号20241227。 | | | 天眼查工商信息显示，大安爱尔眼科医院有限公司，成立于2018年，位于吉林省白城市，是一家以从事卫生为主的企业。企业注册资本780万人民币， 实缴资本150万人民币。 (责任编辑：徐自立) ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The report highlights the increasing support from policies aimed at enhancing service consumption, particularly in the healthcare sector, indicating potential investment opportunities in medical services [2][11] - The "reward economy" is emerging as a new consumption model, where consumers are more willing to spend on non-essential goods and services, especially in healthcare, after meeting basic needs [13][14] - The medical services market in China is projected to reach approximately 8.74 trillion yuan by 2025, with a year-on-year growth rate exceeding 10% [15] Summary by Sections Market Performance - The overall A-share market declined by 0.07%, with the pharmaceutical and biotechnology sector down by 0.14%, underperforming the broader market [23] - Within the sector, chemical pharmaceuticals fell by 1.74%, while medical services and medical devices saw increases of 0.55% and 1.16%, respectively [23] Policy Support - Recent policies have focused on boosting service consumption, with a clear goal of enhancing service quality and expanding supply in key areas such as healthcare [11][12] - The government aims to stimulate demand through financial tools and support for service industries, which is expected to benefit the healthcare sector significantly [11] Investment Opportunities - Companies such as Aier Eye Hospital and Guosheng Tang are highlighted as leading firms in the medical services sector, benefiting from their innovative capabilities and market positioning [16][19] - The report suggests focusing on companies with strong optionality and innovative business models in the medical services space [16] Company Forecasts and Ratings - Major companies in the sector, including Mindray Medical, WuXi AppTec, and Aier Eye Hospital, are rated as "Outperform" with positive profit forecasts for the coming years [4][32] - For instance, Aier Eye Hospital is expected to see significant growth driven by new refractive surgery techniques [19] Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector is reported at 37.07x, compared to the overall A-share market at 20.54x [28]

Group 1 - The "Annual ESG Pioneer Award (Large Market Capitalization)" recognizes companies that balance economic efficiency with social responsibility, highlighting their contributions to environmental, social, and governance (ESG) practices [1] - Ten companies, including Aier Eye Hospital, Beike, Bosideng, Mengniu Dairy, CATL, Tongcheng Travel, Weichai Power, China Feihe, China State Construction International, and Sinotruk, received the award [1] - The evaluation process involved quantitative data analysis and expert review to determine the final results of the award [1] Group 2 - The "Golden Award" aims to create a reference list of the most valuable listed companies and unicorns in the investment community, covering all listed companies on major exchanges including HKEX, SSE, SZSE, NYSE, and NASDAQ [2]